## ARWR: Arrowhead Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -4.1% below STRENGTH zone (3.0-6.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-1.9% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($56.39)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock**
- Source: Business Wire | 20260107T001038 | Neutral | Relevance: 100%
- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) intends to offer $500 million in convertible senior notes due 2032 and $200 million in common stock. The company plans to use the net proceeds for general corporate purposes, including R&D, clinical trials, commercialization activities, and potential prepayment of existing credit facilities, with a portion also funding capped call transactions. J.P. Morgan and Jefferies are acting as joint book-running managers for these separate public offerings.

**2. Arrowhead Shoots For Obesity With RNAi, Shows Weight Loss Success**
- Source: Citeline News & Insights | 20260106T221038 | Bullish | Relevance: 100%
- Arrowhead Pharmaceuticals is making strides in obesity treatment using RNA interference (RNAi) technology. The company has reported success in weight loss, positioning itself as a potential contender in the competitive obesity market. This development could represent a novel therapeutic approach for managing obesity.

**3. Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition**
- Source: Business Wire | 20260106T123207 | Bullish | Relevance: 100%
- Arrowhead Pharmaceuticals announced promising interim results from clinical trials of its RNAi-based obesity candidates, ARO-INHBE and ARO-ALK7. In obese patients with type 2 diabetes, ARO-INHBE in combination with tirzepatide nearly doubled weight loss and tripled visceral, total, and liver fat reductions compared to tirzepatide alone. The data also showed robust single-agent activity and the first human demonstration of adipocyte gene target silencing with an RNAi therapeutic.

**4. Arrowhead Pharma Shares in Focus After $2.5M Insider Sale**
- Source: Eudaimonia and Co | 20260106T070907 | Somewhat-Bullish | Relevance: 100%
- Arrowhead Pharmaceuticals' Chief Medical Officer, James C. Hamilton, sold $2.5 million worth of company stock, following a similar sale by the CEO earlier this month. These sales come amidst strong stock performance due to advancements in the company's RNA interference drug pipeline and recent positive developments like the approval of REDEMPLO by Health Canada and progress in clinical trials. Analysts view these insider sales as planned under a pre-arranged trading plan rather than a negative indicator.

**5. Canada clears at-home injection for rare, painful FCS disorder**
- Source: Stock Titan | 20260105T123253 | Bullish | Relevance: 100%
- Health Canada has approved REDEMPLOâ„¢ (plozasiran) for the at-home treatment of Familial Chylomicronemia Syndrome (FCS), a rare condition causing extremely high triglyceride levels and acute pancreatitis risk. Developed by Arrowhead Pharmaceuticals, REDEMPLO is the first and only siRNA medicine approved for FCS in Canada, allowing self-administration every three months. This approval marks a significant advancement for Canadian patients with limited treatment options.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 6, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2026-01-07 | Goldman Sachs | $85 | $50 | +70% |
| 2026-01-07 | Morgan Stanley | $81 | $48 | +69% |
| 2026-01-07 | Chardan Capital | $80 | $60 | +33% |
| 2025-12-17 | Piper Sandler | $100 | $70 | +43% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2026-01-07 | Goldman Sachs | main | Neutral |
| 2026-01-07 | Morgan Stanley | main | Equal-Weight |
| 2026-01-07 | Chardan Capital | main | Buy |
| 2025-12-17 | Piper Sandler | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 9 ($0.22M) |
| Sells | 11 ($12.27M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 54.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 1 |

**Top Holders:**
- Blackrock Inc.: 14.9% (+4.1%)
- Vanguard Group Inc: 11.8% (+3.3%)
- Avoro Capital Adviso: 8.0% (+2.8%)
- State Street Corpora: 4.7% (+0.4%)
- FMR, LLC: 4.2% (+11.4%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-1.9% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $12M sold (11 transactions in 90 days).
3. Elevated short interest (9.8%): bears positioning against stock.

### Catalysts

- Analyst target momentum: 6 raises (avg +50%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

Balance sheet: strong liquidity (4.9x). Revenue declining -34% YoY, concerning. Analyst sentiment positive (6 raises, avg +50%, $85 target (+29%)). Insider selling cluster ($12.3M in 90 days), potential headwind. Institutional flow bullish (8 buying vs 1 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.1B |
| Beta | 1.22 |
| 52W Range | $9.57 - $76.76 |
| Short Interest | 9.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -1.32 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 deteriorating from -2.2% to -4.1% (-1.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.1pp (needs >3.0% for momentum thesis). Underperforming sector by 6.3pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 2.27x) but short-term weakness (below SMA20). MACD histogram bearish (-1.19), momentum weakening. RSI neutral at 53. OFD pattern: -DLH (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -4.09% (CS: 8) | Weak |
| RSI_14 | 53.3 | Neutral |
| MACD Histogram | -1.19 | Bearish |
| vs SMA20 | 0.965x | Below |
| vs SMA50 | 1.198x | Above |
| vs SMA200 | 2.271x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $65.69
- **Stop Loss:** $56.39 (14.2% risk)
- **Target:** $74.99 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 129
- **Position Value:** $8,474.01
- **Portfolio %:** 8.47%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with balanced risk appetite. VIX at 15.38 sits in the normal range (18th percentile of 52-week) with modest upward drift, while yield curve remains positively sloped (+62bps 10Y-3M) supporting risk assets. Breadth at 59.5% shows healthy participation, though elevated put/call ratio (1.12) suggests some hedging activity. FOMC 20 days out provides runway for current conditions to persist.*

### Earnings

**Next:** 2026-02-09 (Est: $-0.10)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.16 | $-0.18 | -14.4% |
| 2025Q2 | $-1.10 | $-1.26 | -14.4% |
| 2025Q1 | $-0.46 | $2.75 | +695.0% |
| 2024Q4 | $-0.72 | $-1.39 | -92.2% |

---
*RULE-based L3 | 2026-01-08 08:02 | MRS_10*